Palo Alto Investors

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Peak Bio is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for oncology, inflammatory diseases, and rare conditions. The company aims to address significant unmet medical needs through its innovative drug development efforts. By focusing on these critical areas, Peak Bio seeks to advance treatment options and improve patient outcomes.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

NewLeaf Symbiotics, Inc. is an agriculture technology company based in Saint Louis, Missouri, dedicated to the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on naturally occurring bacteria, particularly pink pigmented facultative methylotrophs, which are utilized across various agricultural sectors, including row crops, vegetables, fruits, and ornamental plants. NewLeaf Symbiotics conducts extensive laboratory, greenhouse, and field trials to validate the effectiveness of its products, providing farmers with sustainable solutions to combat plant diseases and improve agricultural productivity. Originally founded as TrophoMax, LLC in 2011, the company rebranded in July 2012 to better reflect its mission and objectives in the agricultural biotechnology space.

NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Fisker, Inc. is an American company headquartered in Manhattan Beach, California, that designs and manufactures electric vehicles and mobility solutions. The company focuses on creating eco-friendly vehicles that evoke emotional connections, aligning with its mission to promote a sustainable future for all. Fisker aims to position itself as an e-mobility service provider, emphasizing the development of innovative electric vehicles that are both environmentally friendly and desirable to consumers. Historically, Fisker Automotive gained recognition for the Fisker Karma, which was among the first luxury plug-in hybrid electric vehicles, but production was halted due to financial challenges. Today, Fisker, Inc. continues to pursue advancements in electric mobility, striving to revolutionize the automotive industry with its commitment to sustainability and design.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

Gemfire Corporation, founded in 1995, operates in the field of high-performance telecom and specialty components, utilizing advanced planar semiconductor processing technology. The company develops innovative optical solutions tailored for system integrators, leveraging its Gemfire PhotonICTM technology platform to enable wafer-scale processing. This approach allows for the efficient production of various optical components, including Athermal and standard Arrayed Waveguide Gratings (AWGs), Tunable Optical Devices (TODCs), Variable Optical Attenuators (VOAs), and Wavelength Multiplexers (VMUXs). Gemfire's primary operations are based in Livingston, Scotland, with additional aerospace support and telecom manufacturing facilities located in Fremont, California.

Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.

Mercator MedSystems, Inc. is a medical technology company based in Emeryville, California, specializing in catheter-guided microfluid injection systems for the targeted delivery of therapeutic agents. The company offers Cricket and Bullfrog micro-infusion catheters, which facilitate the direct injection of therapies through blood vessel walls into deep tissues. These products address conditions such as blood vessel restenosis, inflammation following vascular injury, and peripheral artery disease. Mercator's technology allows for the infusion of drugs, genes, and cells without compromising their viability or potency, making it suitable for therapies ranging from plaque stabilization in diseased vessels to stem cell transplantation and gene therapies. By enabling site-specific delivery, Mercator MedSystems aims to enhance patient outcomes in vascular disease, oncology, and regenerative medicine, while paving the way for innovative treatments in these areas. The company was established in 1999 and was previously known as Endobionics, Inc.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Deem, Inc. is a technology company specializing in Commerce-as-a-Service (CaaS) solutions tailored for the business travel industry. Founded in 1999 and headquartered in San Francisco, California, Deem offers a comprehensive cloud-based suite of applications that streamline travel, expense management, and purchasing for companies. Its platform empowers organizations to manage travel bookings for flights, hotels, and ground transportation while ensuring compliance with corporate spending policies. Additionally, Deem enables merchants to effectively promote and sell their products and services through various channels, enhancing customer engagement with options such as card-linked offers and corporate discounts. The company's focus is on simplifying business travel for employees, reducing costs for employers, and creating profitable opportunities for service providers. Deem operates as a subsidiary of Enterprise Holdings, Inc.

SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

SkyPilot Networks is a prominent provider of broadband wireless equipment designed for service providers, municipalities, and public safety agencies to efficiently deploy various network services. These services include last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. The company's innovative solution employs a patented multi-hop point-to-multipoint architecture that enhances reach, reduces interference, and optimizes spectral efficiency. This technology results in a scalable, reliable, and deterministic broadband wireless network that simplifies design, increases deployment flexibility, and lowers both equipment and operational costs. SkyPilot's products include the SkyPilot Connector Mini and Pro, which offer cost-effective customer premises equipment for long-range connectivity, and the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record, SkyPilot has delivered its systems to customers in over 50 countries and is headquartered in Santa Clara, California.

Speedera Networks, Inc. was founded in 1999 and is headquartered in Santa Clara, California. The company specializes in distributed application hosting and content delivery services, catering to both industry and government sectors. It offers a range of on-demand services designed to address challenges related to performance, scalability, availability, and security of distributed applications and websites. In 2005, Speedera Networks was acquired by Akamai Technologies Inc.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

Conductus specializes in producing superconducting wire, known as Conductus®, which is utilized in the creation of superconductor electrical devices across various applications. This high current carrying conductor offers substantial performance improvements, enhanced power density, reduced size, and significant cost advantages compared to traditional copper and aluminum wire. The wire is manufactured using a proprietary deposition process called RCE-CDR. Additionally, Conductus develops electronic components and systems based on high-temperature superconductors for the global telecommunications market, utilizing thin-film technology derived from yttrium barium copper oxide. Their products cater to various telecommunications standards, including TDMA, CDMA, GSM, and analog base stations.